General Information of Drug (ID: DMM1GXI)

Drug Name
DL-guanidinoethylmercaptosuccinic acid Drug Info
Synonyms
77482-44-1; gemsa; guanidinoethylmercaptosuccinic acid; DL-guanidinoethylmercaptosuccinic acid; CHEMBL560871; GUANIDINOETHYLMERCAPTO-SUCCINIC ACID; Butanedioic acid,2-[[2-[(aminoiminomethyl)amino]ethyl]thio]-; 2-[2-(diaminomethylideneamino)ethylsulfanyl]butanedioic acid; Guanidinoethyl-Mercaptosuccinic Acid; AC1L1FZW; AC1Q5SXD; 2-[(2-carbamimidamidoethyl)sulfanyl]succinic acid; AC1Q50E8; SCHEMBL1765999; CTK5E4534; 2-Guanidinoethylthiosuccinic acid; MolPort-004-964-125; (2-Guanidinoethylthio)succinic acid; BDBM50296412
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
3464
CAS Number
CAS 77482-44-1
TTD Drug ID
DMM1GXI

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Discontinued Drug(s)
Investigative Drug(s)
Drug(s) Targeting Carboxypeptidase B2 (CPB2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
SAR-126119 DMKHM7O Cerebrovascular ischaemia 8B1Z Phase 1 [2]
UK-396082 DMFYKDX Thrombosis DB61-GB90 Phase 1 [3]
DS-1040 DMXCN37 Ischemic stroke 8B11.5Z Phase 1 [4]
SAR-104772 DMQ9ZY0 Cerebrovascular ischaemia 8B1Z Phase 1 [5]
AZD-9684 DMHA5ME Thrombosis DB61-GB90 Discontinued in Phase 2 [6]
PMID14640538C3 DMR2L6X Discovery agent N.A. Investigative [7]
DL-benzylsuccinic acid DMHI9ZJ Discovery agent N.A. Investigative [1]
PMID19954973C4 DMDYZE5 Discovery agent N.A. Investigative [3]
3-mercapto-2-(piperidin-3-yl)propanoic acid DMPJBNC Discovery agent N.A. Investigative [8]
6-Amino-2-(1H-imidazol-4-yl)-hexanoic acid DMMUE05 Discovery agent N.A. Investigative [9]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Carboxypeptidase B2 (CPB2) TTP18AY CBPB2_HUMAN Inhibitor [1]

References

1 A new type of five-membered heterocyclic inhibitors of basic metallocarboxypeptidases. Eur J Med Chem. 2009 Aug;44(8):3266-71.
2 TAFIa inhibitors in the treatment of thrombosis. Curr Opin Drug Discov Devel. 2008 Jul;11(4):480-6.
3 Oxygenated analogues of UK-396082 as inhibitors of activated thrombin activatable fibrinolysis inhibitor. Bioorg Med Chem Lett. 2010 Jan 1;20(1):92-6.
4 Clinical pipeline report, company report or official report of Daiichi Sankyo.
5 Carboxypeptidase U (TAFIa): a new drug target for fibrinolytic therapy . Journal of Thrombosis and Haemostasis Volume 7, Issue 12, pages 1962-1971, December 2009.
6 Clinical pipeline report, company report or official report of AstraZeneca.
7 Synthesis and evaluation of imidazole acetic acid inhibitors of activated thrombin-activatable fibrinolysis inhibitor as novel antithrombotics. J Med Chem. 2003 Dec 4;46(25):5294-7.
8 3-Mercaptopropionic acids as efficacious inhibitors of activated thrombin activatable fibrinolysis inhibitor (TAFIa). Bioorg Med Chem Lett. 2007 Mar 1;17(5):1349-54.
9 Imidazole acetic acid TAFIa inhibitors: SAR studies centered around the basic P(1)(') group. Bioorg Med Chem Lett. 2004 May 3;14(9):2141-5.